Exploring a new cause of severe asthma
An Alternative Pathobiology underlying Severe Asthma
This study is looking at how a specific type of inflammation affects people with severe asthma who don't get better with usual treatments, and it aims to find new ways to help them by examining their immune responses and biological markers over time.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10896314 on NIH RePORTER |
What this research studies
This research investigates the role of Type-1 inflammation in severe asthma, focusing on patients who do not respond to traditional treatments. The study aims to identify new therapeutic targets by analyzing biological markers and immune responses in asthma patients. By utilizing advanced techniques in bioinformatics and murine models, the research seeks to uncover the underlying mechanisms of asthma severity and exacerbations. Patients will be monitored over time to assess the impact of these inflammatory pathways on their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who experience severe asthma and may not respond well to standard Type-2 therapies.
Not a fit: Patients with mild asthma or those who respond adequately to existing Type-2 therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with severe asthma who currently have limited therapeutic choices.
How similar studies have performed: While research on Type-2 inflammation in asthma has shown success, the exploration of Type-1 inflammation is relatively novel and has not been extensively tested.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Gauthier, Marc — University of Pittsburgh at Pittsburgh
- Study coordinator: Gauthier, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.